AlphAIAlphAI — Financial news for AI agents
thepharmaletter.comSEP 232 min read$AMGN

Amgen touts Phase III success in systemic Sjögren's disease

Amgen reported positive Phase III results for dazodalibep in treating systemic Sjögren's disease, meeting primary endpoints. Shares rose 3.4% to $407.57. The study showed significant improvement in disease activity at Week 48, with early and sustained effects.

Original reporting
thepharmaletter.com
Published Sep 23, 2026, 8:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 10:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amgen touts Phase III success in systemic Sjögren's disease — source image
Source · thepharmaletter.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The trial met its primary endpoint with statistically significant improvement in ESSDAI scores, indicating a potentially market‑moving therapeutic advance.

02

Market read

Positive trial data could drive Amgen's stock higher and influence peer biotech valuations.

03

What to watch

Regulatory timeline and competitive pipeline could temper upside.

Relevance 9/10Novelty 9/10Timing: after-hours yesterday

Background

Amgen (NASDAQ: AMGN) announced top‑line data from its Phase III study of dazodalibep in systemic Sjögren's disease.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen reported positive Phase III OASIZ 301 trial results for dazodalibep in systemic Sjögren's disease, causing a 3.4% share rise.

Expected impact

upward pressure in the short term

Evidence & confidence

Phase III success is material for a large biotech and often leads to price appreciation.

Market effects

Sector

May lift sentiment for the broader autoimmune biotech sector.

Regional

U.S. biotech indices could see modest gains.

Global

Potential interest from global investors tracking biotech breakthroughs.

Counterpoint

What could challenge this read

Skeptics may question long-term efficacy or commercial viability despite Phase III success.

Key entities

  • company
    Amgen

    U.S. biotech firm developing dazodalibep.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 23
$AMGNHighAI 8/10

Amgen (AMGN) Following Its Sjögren's Trial Win Through A Valuation Lens

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep in treating Sjögren's disease. The stock has gained 25.21% YTD and 47% over 1 year. Analysts debate its valuation, with some arguing it's 14% overvalued at $410.24, while a DCF model suggests it's undervalued at $669.25. The company's pipeline and debt levels are key considerations.

simplywall.st3 min
SEP 22
$AMGNMedAI 8/10

AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’

Amgen (AMGN) shares rose 4% after reporting positive late-stage trial results for dazodalibep in treating systemic Sjögren’s disease, a condition with no approved therapy. The trial showed significant improvement in disease intensity. Citi noted positive results but awaits more details, maintaining a Neutral rating and $405 price target. AMGN is up 25% year-to-date.

stocktwits.com2 min
SEP 22
$AMGNMedAI 8/10

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data - Amgen (NA

Amgen (AMGN) reported positive results from its Phase 3 OASIZ 301 trial for dazodalibep in treating Sjögren’s disease, meeting the primary endpoint. The study showed statistically significant improvements in disease activity scores. Adverse events were low and similar to placebo. Amgen plans to share full data at a future conference and awaits results from another trial, OASIZ 303, for potential FDA filing. Shares rose 3.54% to $407.08. Analysts expect two positive trials for approval.

benzinga.com4 min
SEP 22
$AMGNMedAI 8/10

AMGN Looks 10.5% Overvalued on GF Value™ Amid Dividend Sustainab

Amgen (AMGN) reported preliminary positive Phase 3 trial results for dazodalibep, a treatment for systemic Sjogren's syndrome. Citi maintains a Neutral rating with a $405 price target. The stock offers a 2.44% dividend yield, a 44% payout ratio, and a 7.1% 3-year dividend growth rate. GF Value™ suggests the stock is 10.5% overvalued, while the GF Score™ is 86/100, reflecting strong profitability and growth but weaker financial strength and momentum.

gurufocus.com2 min
SEP 22
$AMGNMedAI 9/10

Amgen’s dazodalibep meets primary endpoint in Sjögren’s trial

Amgen (AMGN) reported that its Phase 3 trial of dazodalibep met the primary endpoint in treating Sjögren’s disease, showing significant improvement at Week 48. The study enrolled 621 patients. Dazodalibep is not yet FDA-approved. Amgen plans to share detailed data at a future medical meeting. The company's Phase 3 OASIZ 303 study is expected to complete in Q4 2026.

investing.com2 min